Cargando…

Significance of Vitamin D Receptor Gene Polymorphisms for Risk of Hepatocellular Carcinoma in Chronic Hepatitis C

BACKGROUND/AIMS: Biological and epidemiological data suggest that vitamin D levels may influence cancer development. Several single nucleotide polymorphisms have been described in the vitamin D receptor (VDR) gene in association with cancer risk. We aimed to investigate the association of VDR gene p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hung, Chao-Hung, Chiu, Yi-Chun, Hu, Tsung-Hui, Chen, Chien-Hung, Lu, Sheng-Nan, Huang, Chao-Min, Wang, Jing-Houng, Lee, Chuan-Mo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202781/ https://www.ncbi.nlm.nih.gov/pubmed/24894441 http://dx.doi.org/10.1016/j.tranon.2014.05.001

Ejemplares similares

Neutrophil-to-Lymphocyte Ratio as a Predictor of Response to Peginterferon plus Ribavirin Therapy for Chronic Hepatitis C
por: Kuo, Ming-Te, et al.
Publicado: (2014)

Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir
por: Chen, Chien-Hung, et al.
Publicado: (2017)

Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients
por: Lee, Chuan-Mo, et al.
Publicado: (2016)

Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib
por: Kuo, Yuan-Hung, et al.
Publicado: (2022)

Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C
por: Huang, Chao-Min, et al.
Publicado: (2017)

HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral
por: Chang, Kuo-Chin, et al.
Publicado: (2022)

Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment
por: Ma, Te-Ling, et al.
Publicado: (2019)

The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals
por: Lee, Yu-Chi, et al.
Publicado: (2019)

Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C
por: Yen, Yi-Hao, et al.
Publicado: (2019)

Ultrasound is highly specific in diagnosing compensated cirrhosis in chronic hepatitis C patients in real world clinical practice
por: Yen, Yi-Hao, et al.
Publicado: (2019)

Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents
por: Huang, Chao-Min, et al.
Publicado: (2017)

The Changes of Liver Stiffness and Its Associated Factors for Chronic Hepatitis B Patients with Entecavir Therapy
por: Kuo, Yuan-Hung, et al.
Publicado: (2014)

Hepatic Clostridium Perfringens Abscess Formation after Radiofrequency Ablation Therapy for Hepatocellular Carcinoma: Report of a Rare Case
por: Wang, Ming-Hung, et al.
Publicado: (2021)

APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level
por: Yen, Yi-Hao, et al.
Publicado: (2018)

Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data
por: Yen, Yi-Hao, et al.
Publicado: (2019)

Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C
por: Lin, Sheng Feng, et al.
Publicado: (2020)

MicroRNAs in Hepatocellular Carcinoma: Carcinogenesis, Progression, and Therapeutic Target
por: Hung, Chao-Hung, et al.
Publicado: (2014)

A Mac-2 Binding Protein Glycosylation Isomer-Based Risk Model Predicts Hepatocellular Carcinoma in HBV-Related Cirrhotic Patients on Antiviral Therapy
por: Chen, Chien-Hung, et al.
Publicado: (2022)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma
por: Wang, Hung-Wei, et al.
Publicado: (2020)

A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute Exacerbation
por: Hung, Chao-Hung, et al.
Publicado: (2017)

Short Half-Life of Des-γ-Carboxy Prothrombin Is a Superior Factor for Early Prediction of Outcomes of Hepatocellular Carcinoma Treated with Radiofrequency Ablation
por: Yao, Chih-Chien, et al.
Publicado: (2023)

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Factors Predicting HBsAg Seroclearance and Alanine Transaminase Elevation in HBeAg-Negative Hepatitis B Virus-Infected Patients with Persistently Normal Liver Function
por: Chien, Tai-Long, et al.
Publicado: (2016)

Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib
por: Kee, Kwong-Ming, et al.
Publicado: (2014)

Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment
por: Chiu, Shao-Ming, et al.
Publicado: (2020)

Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation
por: Chen, Hsin-Yeh, et al.
Publicado: (2020)

Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation
por: Kuo, Yuan-Hung, et al.
Publicado: (2023)

Predictive Effects of Inflammatory Scores in Patients with BCLC 0-A Hepatocellular Carcinoma after Hepatectomy
por: Huang, Pao-Yuan, et al.
Publicado: (2019)

Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse
por: Tseng, Tzu-Ning, et al.
Publicado: (2022)

A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfected patients treated with interferon and ribavirin in an Asian cohort
por: Yen, Yi-Hao, et al.
Publicado: (2018)

Comparison of Therapeutic Response and Clinical Outcome between HCV Patients with Normal and Abnormal Alanine Transaminase Levels
por: Wu, Cheng-Kung, et al.
Publicado: (2016)

MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin
por: Yen, Yi-Hao, et al.
Publicado: (2016)

Associated Factors for Metabolic Syndrome in the Older Adults with Chronic Virus Hepatitis in the Community
por: Kuo, Yuan-Hung, et al.
Publicado: (2016)

The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan
por: Tsai, Ming-Chao, et al.
Publicado: (2021)

Does Nucleos(t)ide Analogues Treatment Affect Renal Function in Chronic Hepatitis B Patients Who Have Already Decreased eGFR? A Longitudinal Study
por: Tsai, Ming-Chao, et al.
Publicado: (2016)

Low-dose nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2022)

Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment
por: Yeh, Jen-Hao, et al.
Publicado: (2015)

Long-Term Effect of Interferon Plus Ribavirin on Hepatitis B Surface Antigen Seroclearance in Patients Dually Infected with Hepatitis B and C Viruses
por: Yeh, Ming-Lun, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_mpbuhn5hnk7s9oaa924rurn8uo